1-20 of 324866
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal: Blood
Blood (2025) 146 (4): 408–409.
Published: 2025
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood (2025) 146 (4): 399–400.
Published: 2025
Journal Articles
Journal Articles
Images
MPL-dependent and -independent features of JAK2V617F-driven MPN phenotypes. MPL plays a critical role in JAK2V617F MPNs by driving long-term self-renewal of HSCs, promoting megakaryocyte (MK) hyperplasia, thrombocytosis, and progression to MF. In contrast, other hallmark features of JAK2V617F MPNs such as erythrocytosis, leukocytosis, splenomegaly, and the production of proinflammatory cytokines that contribute to spleen fibrosis occur independently of MPL signaling. Figure created with Biorender.com.
Published: 2025
MPL-dependent and -independent features of JAK2V617F-driven MPN phenotypes. MPL plays a critical role in JAK2V617F MPNs by driving long-term self-renewal of HSCs, promoting megakaryocyte (MK) hyperplasia, thrombocytosis, and progression to MF. In contrast, other hallmark features of JAK2V617F MPNs s... More about this image found in MPL-dependent and -independent features of JAK2V617F-driven MPN phenotypes....
Images
The B-cell developmental stage of arrest impacts InO sensitivity in B-ALL samples. Escherich et al used bulk RNA sequencing and a gene expression reference for normal B lymphopoiesis to infer the relative contribution of transformed B-cell developmental stages to individual B-ALL samples. The relative proportion of more immature Pre-pro B cells increased in cases with Ino resistance, while the relative proportion of more mature pro B cells decreases. The InO target antigen CD22 is a direct target for transcriptional regulation by EBF1, which are both initiated at the Pre-pro B stage of normal B lymphopoiesis (CD22 and EBF1 expression taken from https://scminer.stjude.org).7 Professional illustration by Patrick Lane, ScEYEnce Studios.
Published: 2025
The B-cell developmental stage of arrest impacts InO sensitivity in B-ALL samples. Escherich et al used bulk RNA sequencing and a gene expression reference for normal B lymphopoiesis to infer the relative contribution of transformed B-cell developmental stages to individual B-ALL samples. The relati... More about this image found in The B-cell developmental stage of arrest impacts InO sensitivity in B-ALL s...
Images
Postimmunotherapy lineage switch. In the international Project EVOLVE cohort, postimmunotherapy lineage switch (LS) occurred primarily in KMT2A-rearranged B-ALL; however, multiple other B-ALL subtypes were represented. LS occurred after CD19 and/or CD22 targeting CAR-T therapy, blinatumomab and inotuzumab ozogamicin---it remains unclear whether immunotherapy directly induces LS or selects for preexisting myeloid or less differentiated clones. B-cell receptor sequencing of pre- and post-LS leukemia suggests that LS may occur via direct B-ALL to myeloid transdifferentiation, but it has also been proposed to arise from primitive precursor populations. LS occurs rapidly, and post-LS treatment outcomes are dismal. Structured collaborative translational research to address the mechanisms that drive LS will likely lead to improved outcomes. ALAL, acute leukemia of ambiguous lineage; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; Blin, blinatumomab; CAR-T, chimeric antigen receptor T cell; HSC, hematopoietic stem cell; Ino, inotuzumab ozogamicin; LS, lineage switch; NOS, not otherwise specified; mOS, median overall survival; MPP, multipotent progenitor cell.
Published: 2025
Postimmunotherapy lineage switch. In the international Project EVOLVE cohort, postimmunotherapy lineage switch (LS) occurred primarily in KMT2A-rearranged B-ALL; however, multiple other B-ALL subtypes were represented. LS occurred after CD19 and/or CD22 targeting CAR-T therapy, blinatumomab and inot... More about this image found in Postimmunotherapy lineage switch. In the international Project EVOLVE cohor...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal: Blood
Blood (2025) 146 (4): 437–455.
Published: 2025
Includes: Supplemental data
Journal Articles
Journal Articles
Journal Articles